Downloads: 168

Files in This Item:
File Description SizeFormat 
24_0779.pdf1 MBAdobe PDFView/Open
Title: 二重盲検法によるFosfomycin(FOM)とCarbenicillin indanyl(I-CBPC)の複雑性尿路感染症に対する薬効比較
Other Titles: A DOUBLE-BLIND COMPARISON OF THE EFFICACY OF FOSFOMYCIN AND CARBENICILLIN INDANYL IN COMPLICATED URINARY TRACT INFECTIONS
Authors: 宍戸, 仙太郎  KAKEN_name
山中, 雅夫  KAKEN_name
渋谷, 昌良  KAKEN_name
松下, 鈆三郎  KAKEN_name
海法, 裕男  KAKEN_name
斎藤, 克之  KAKEN_name
菅原, 奎二  KAKEN_name
斎藤, 武志  KAKEN_name
白井, 将文  KAKEN_name
宮田, 宏洋  KAKEN_name
中野, 修道  KAKEN_name
竹内, 睦男  KAKEN_name
鈴木, 富夫  KAKEN_name
千葉, 隆一  KAKEN_name
加藤, 正和  KAKEN_name
新井, 元凱  KAKEN_name
Author's alias: Shishito, Sentaro
Yamanaka, Masao
Shibuya, Masayoahi
Matsushita, Shozaburo
kaiho, Hiroo
Saito, Katsuyuki
Sugawara, Keiji
Saito, Takeshi
Shirai, Masafumi
Miyata, Koyo
Nakano, Nobumichi
Takeuchi, Mutsuo
Suzuki, Tomio
Chiba, Ryuichi
Kato, Masakazu
Arai, Motoyoshi
Issue Date: Sep-1978
Publisher: 京都大学医学部泌尿器科学教室
Journal title: 泌尿器科紀要
Volume: 24
Issue: 9
Start page: 779
End page: 797
Abstract: Comparative double blind trial of fosfomycin calcium (FOM) and carbenicillin indanyl sodium (I-CBPC) was performed in 72 patients of complicated urinary tract infection with Pseudomonas or Proteus species. Patients were treated orally for a week at a daily dose of 2 g of FOM or I-CBPC. The results obtained were summarized as follows: 1. The background characteristics of two groups were statistically analyzed, and they were to be satisfied in their uniformity as the subject of this trial. 2. The degree of improvement of symptoms and urinary findings, and the change of bacterial count and species in urine were also compared and were not significantly different between the two groups. 3. The clinical effects were excellent in 4 cases, good in 7 cases, fair in 15 cases, and poor in 11 cases out of 37 cases of the FOM group, and excellent in 4 cases, good in 12 cases, fair in 11 cases, and poor in 8 cases out of 35 cases of the I-CBPC group. No significant difference was obtained between the two groups. 4. The incidence of adverse reactions was 2 out of 41 cases of the FOM group (4.9%) and lout of 43 cases of the I-CBPC group (2.3%), showing no significant difference. Considering the data described above, there was no significant difference between FOM and 1-CBPC groups on overall clinical efficacy, utility, improvement of symptoms and findings, and incidence of adverse reactions.
URI: http://hdl.handle.net/2433/122255
Appears in Collections:Vol.24 No.9

Show full item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.